1INTRODUCTIONBreast cancer is the most common malignancy and it ranks the first in cancer deaths in females. Adjuvant systemic therapies are used to reduce the risk of death and recurrence by eliminating residual and systemic micrometastases after local control in breast cancer. Disease recurrence is seen in 35–90% of lymph node positive patients and 10–30% of lymph node negative patients who receive only local treatment for occult micrometastatic disease.Selection between local and systemic therapies is done considering the different predictive and prognostic factors. Prognostic factors at the time of diagnosis give information about the course of the disease and the predictive factors give information about the probability of response to treatment that will be given. These factors include tumor histology, tumor size, and axillary lymph node status, hormone receptor status, human epidermal growth factor receptor (HER2) status, other concomitant diseases, age and menopausal status of the patient. Pathological assessment of tumor size, lymph node involvement, proliferation rate (Ki67), tumor grade peritumoral vascular invasion and age, endocrine receptor status, HER2 status of the patient are important predictive factors and guide the way in the choice of adjuvant treatment in early breast cancer. Expression of estrogen receptor (ER) and progesterone receptor
Asia-Pacific Journal of Clinical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera